Haya Therapeutics

Eli Lilly & Co. (NYSE: LLY), a leading figure in the pharmaceutical industry, has embarked on a drug discovery partnership with Switzerland’s Haya Therapeutics, a move that underscores its commitment to advancing its anti-obesity portfolio. The collaboration will tap into Haya’s cutting-edge expertise in the dark genome, the largely non-protein-coding…